Skip to main content
Cellid Co., Ltd. logo

Cellid Co., Ltd. — Investor Relations & Filings

Ticker · 299660 ISIN · KR7299660001 KO Manufacturing
Open in API
Filings indexed 393 across all filing types
Latest filing 2020-03-25 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 299660

About Cellid Co., Ltd.

http://www.cellid.co.kr

Cellid Co., Ltd. is a research and development biotechnology company focused on immunotherapeutic vaccines. The company's activities are centered on two proprietary technology platforms: CeliVax for anti-cancer immunotherapy and an adenovirus vector platform for infectious disease vaccines. The CeliVax platform is used to develop personalized vaccines that utilize a patient's own B cells and monocytes to target specific cancer antigens. The adenovirus vector platform enables the rapid development of safe, non-replicating viral vector vaccines, with a key application being its COVID-19 vaccine candidate. Cellid's pipeline is built upon these core technologies to address unmet medical needs in oncology and virology.

Recent filings

Filing Released Lang Actions
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 95% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options). It is addressed to the Financial Services Commission/Korea Exchange and details the issuance of stock options to specific individuals, including the number of shares, exercise price, and valuation methodology. This type of disclosure regarding capital structure changes and equity-based compensation falls under the category of 'Share Issue/Capital Change' (SHA) in the provided taxonomy.
2020-03-25 Korean
투자판단관련주요경영사항(항암면역치료백신 BVAC-P의 임상 1상 시험 계획 승인)
Regulatory Filings Classification · 95% confidence The document is a regulatory filing from the Korean company Cellid regarding the approval of a Phase 1 clinical trial for their cancer immunotherapy vaccine, BVAC-P. It details the clinical trial stage, purpose, and regulatory approval from the Ministry of Food and Drug Safety. Since this is a specific regulatory announcement regarding business operations and clinical trial status that does not fit into financial reporting or specific corporate governance categories, it is classified as a Regulatory Filing (RNS).
2020-03-24 Korean
감사보고서제출
Audit Report / Information Classification · 98% confidence The document is titled '감사보고서 제출' (Submission of Audit Report) and provides the audit opinion, key financial data, and auditor information for the company Cellid. It is a regulatory filing that summarizes the results of an external audit, which fits the definition of an Audit Report (AR). Although it is a short summary, it contains the core audit findings rather than just announcing the availability of a separate document, thus it is classified as an Audit Report. FY 2019
2020-03-13 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Notice of Convocation of the Annual General Meeting' (주주총회소집공고) for Cellid Co., Ltd. It includes the meeting date, location, agenda items (approval of financial statements, election of directors, etc.), and management reference materials (business overview, financial statements). This is a standard proxy solicitation document sent to shareholders to inform them of the upcoming meeting and request their votes. Therefore, it is classified as a Proxy Solicitation & Information Statement.
2020-03-10 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for the company Cellid. It outlines the date, location, and the agenda items (proposals) to be voted on, such as financial statement approval, director appointments, and business purpose changes. This type of document is a standard proxy solicitation material used to inform shareholders of an upcoming meeting and the matters to be decided, which falls under the Proxy Solicitation & Information Statement category.
2020-02-25 Korean
주주총회집중일개최사유신고
AGM Information Classification · 98% confidence The document is a formal regulatory filing submitted by Cellid to disclose the reason for holding their Annual General Meeting (AGM) on a 'concentrated date' (a date when many other companies are also holding their AGMs). It provides the date of the meeting, the justification for the scheduling conflict, and the expected notice date. Since it is a regulatory disclosure regarding meeting logistics rather than the meeting materials themselves or a proxy statement, it falls under the general regulatory filing category.
2020-02-25 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.